Wealth Manager - the site for professional investment managers

Register to get unlimited access to all of Citywire’s Fund Manager database. Registration is free and only takes a minute.

HMRC wins court battle against £80m Matrix tax scheme

HMRC wins court battle against £80m Matrix tax scheme

A  tax avoidance scheme promoted by Matrix Securities has been successfully challenged by HM Revenue & Customs (HMRC) in court.

HMRC said the medical research-based tax avoidance scheme had created £77 million in tax relief.

Eighty three investors invested in a Jersey-registered limited partnership, which claimed to be trading in the UK, focused on creating and exploiting intellectual property from research into vaccines targeting diseases such as HIV, flu and hepatitis B.

The investors used £28 million of their own cash and £86 million in bank loans.

The partnership claimed a first-year trading loss of nearly £193 million, creating £77 million in tax relief. This would have given the investors an almost £50 million return on their personal investments.

However, only £14 million had been spent on medical research, HMRC said.

As a result, a tribunal agreed that individual partners were entitled to a tax relief of no more than £14 million and further, that the £7 million in fees that it paid to a subsidiary of the scheme promoters failed to qualify as tax relief.

The interest relief on the loans that had been used in the scheme was also restricted.

Exchequer Secretary David Gauke said: ‘The government is committed to tackling tax avoidance and will close down those schemes that are artificial and contrived ways of exploiting the rules.

‘Significant reinvestment has been made into HMRC to pursue and challenge the tax dodgers and they will take decisive action to close down schemes with the sole purpose of avoiding paying tax.’

Leave a comment!

Please sign in or register to comment. It is free to register and only takes a minute or two.
Citywire TV
Play Carl Harald Janson: why biotech is on a 20-year bull run

Carl Harald Janson: why biotech is on a 20-year bull run

The manager of the International Biotechnology Trust explains why his confident about the sector's long term prospects.

Brewin's Gutteridge: the opportunities in UK challenger banks

Brewin's Gutteridge: the opportunities in UK challenger banks

In this week's podcast, Brewin Dolphin's Ben Gutteridge and Guy Foster, discuss opportunities in the global financials sector with Aptus' Johnny De La Hey.

Play How BlackRock Income Strategies is positioning for a crash

How BlackRock Income Strategies is positioning for a crash

Adam Ryan keeps his powder dry as he positions the BlackRock Income Strategies investment trust for a market correction. 

Your Business: Cover Star Club

Profile: how Close Brothers gave power back to the regions

Profile: how Close Brothers gave power back to the regions

Almost a year into the role, Close Brothers Asset Management head of wealth management Andy Cumming has highlighted three keys areas of focus

Wealth Manager on Twitter